Twelve Indicted In $4.53 Million Rebate Case Involving Korea’s Dong-A
This article was originally published in PharmAsia News
Instead of providing rebates through its own sales representatives, Korea’s largest domestic company tried to sidestep anti-rebate laws using marketing and distribution agencies to provide rebates to hospitals and doctors.
You may also be interested in...
In its ongoing clamp down against illegal rebate activities in the domestic pharmaceutical industry, South Korea cuts prices of Dong-A ST’s drugs. This follows recent punitive measures against Novartis' Korean subsidiary.
Dong-A Enrolls GSK Korea General Manager On Board Of Directors; GSK Says Move Will Strengthen Alliance, Not Influence
SEOUL - Korea's leading pharma Dong-A Pharmaceutical Co. Ltd. placed GlaxoSmithKline PLC's Korea General Manager Kim Jin-ho on its nine-member board of directors in a follow-up action to GSK's acquisition of a 9.9% stake in Dong-A in May 2010
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.